Cheryl Ho, MD, FRCP(C)

Clinical Associate Professor
University of British Columbia
Medical Oncologist
British Columbia Cancer
Vancouver, BC

Cheryl Ho, MD is a medical oncologist at BC Cancer and Clinical Associate Professor at the University of British Columbia. Her clinical practice focuses on thoracic and head & neck malignancies. Dr. Ho evaluates the impact of therapies proven in clinical trials in the real world through population-based analysis. Her current focus is on developing a learning health care system with a real-world data evidence-generation framework to inform healthcare decision-makers.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Associate Professor, University of Alberta
Medical Oncologist, Cross Cancer Institute
Director, Clinical Trials Unit, Cross Cancer Institute
Provincial Lead, Alberta Lung Cancer Program
Edmonton, AB

Randeep Sangha, MD, is an Associate Professor at the University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.

Dr. Sangha obtained his medical degree from the University of Alberta Faculty of Medicine, where he also completed his his residency in Internal Medicine and Medical Oncology. He then pursued a post-training research fellowship at the University of California, Davis Comprehensive Cancer Center, focusing on thoracic malignancies.

Dr. Sangha is the Director of the Clinical Trials Unit at the Cross Cancer Institute. He also has been the Provincial Lead for the Alberta Lung Cancer Program. His clinical and research interests include treatment of thoracic and hematologic malignancies, as well as developmental and molecular therapeutics.

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg completed medical school and Residency at the University of BC and University of Toronto.  He went onto a Fellowship at Stanford University and has been the Department Head of Radiation Oncology at the BC Cancer Surrey Centre for the past 4 years. He chairs the Lung Radiation Oncology working group with CCTG and is a founding member of CAPRI (Canadian Pulmonary Radiotherapy Investigators Group).

He has been a leader in BC Cancer’s Stereotactic Ablative Body Radiotherapy (SABR) programs and his current research efforts focus on how radiation can alter the course of metastatic disease and (outside of cancer) whether radiation is able to treat heart arrhythmias.

Mara B. Antonoff MD, FACS

Dr. Antonoff completed her undergraduate studies at the University of Pennsylvania and earned her medical degree at the University of Minnesota, where she also completed internship and residency in General Surgery. Dr. Antonoff completed a fellowship in Cardiothoracic Surgery at Washington University in St Louis. She joined MD Anderson in 2014, where she’s currently an Associate Professor of Thoracic and Cardiovascular Surgery and Program Director for Education. She is the Deputy Head of Education for Surgery, as well as the Chair of the GME Committee on Diversity and Disparities. Dr. Antonoff’s research interests include pulmonary metastatic disease, early detection of lung cancer, and local consolidative therapy for stage IV lung cancer. She leads a multi-institutional trial for lung-limited metastatic colorectal cancer, and she is the surgical lead for several trials evaluating the role of local consolidative therapy for metastatic non-small cell lung cancer. She holds several leadership roles in the STS, including chair of the STS Career Development Workforce and its leadership Institute. She currently serves as the Vice President and President-Elect of the WTS. She further holds leadership roles within the AATS, the STSA, the AWS, IASLC, ESTS, and the TSDA, as well as Senior Editorial Board positions for Annals of Thoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, Innovations, CTSNet, and Journal of Thoracic Disease. She is the proud mother of 4 children, aged 5 to 15.

Houda Bahig, MD PhD

Dr Bahig, MD PhD is a radiation oncologist and clinician scientist at the Centre Hospitalier de l’Université de Montréal. She specializes in the treatment of lung and head and neck cancers, with a special interest for the development of pragmatic clinical trials evaluating new technological approaches to individualize radiotherapy, as well as treatment combinations with immunotherapy in oligometastatic disease.

David Baldwin

David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Honorary Professor in the School of Medicine at the University of Nottingham. He is Lead Clinician for Lung Cancer, NHSE and Chair of the UK Clinical Expert Group for Lung Cancer and Mesothelioma. He is Advisor to the UK National Screening Committee, DHSC. He has obtained research grants from a variety of charities and NIHR to a total value of over £35M as applicant and co-applicant. His primary research interests are in CT screening and lung cancer epidemiology. He is leading the novel recruitment work package in the 4-in-the-Lung-Run project. He was lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 250 papers, including three influential guidelines. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group, Chair of the Quality Standards Group on Lung Cancer, Clinical Director of the East Midlands Cancer Alliance and Chair of the Screening Prevention and Early Diagnosis Group for the National Cancer Research Institute.

Hossein Borghaei, DO, MS

Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.

In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic.

Dr. Borghaei is the co-chair of the thoracic committee at Eastern Cooperative Oncology Group (ECOG) and the Chair of the LungMap trial (S1800/S1900). He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. He also is the recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, SITC and ECOG thoracic committee.

Ian Bosdet, PhD, FCCMG

Dr. Bosdet is a Clinical Associate Professor at the University of British Columbia and a Clinical Molecular Geneticist at the Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer. He received degrees in Microbiology and Immunology and in Genetics from the University of British Columbia, followed by clinical fellowship training and Canadian College of Medical Geneticists (CCMG) certification at BC Children’s and BC Women’s Hospitals.

BC Cancer’s CGL is the primary site providing molecular genetics and cytogenetics testing for cancer patients in the province of BC, focused on the identification of acquired and inherited genetic changes to diagnose patients and help direct their care. In addition to his clinical service work at CGL, Dr. Bosdet has an interest in the translation and implementation of new technologies and informatics tools for clinical genetics testing of hematologic and solid tumours.

As a member of the CCMG, he has served on the Education, Ethics, and Public Policy committee and is actively involved in the development of national practice guidelines and policies for genetic and genomic patient care. He teaches undergraduates and medical residents in the UBC Faculty of Medicine and sits on the Program Advisory Committee for the Clinical Genetics Technology program at the BC Institute of Technology (BCIT).

Aadel Chaudhuri, MD, PhD

Aadel Chaudhuri, MD, PhD, is a physician-scientist and Assistant Professor of Radiation Oncology, Genetics, Biomedical Engineering, and Computer Science at the Washington University in St. Louis. He is Leader of the Liquid Biopsy Working Group at the Washington University Siteman Cancer Center, and serves as Co-Chair of the Liquid Biopsy Interest Group within the National Institutes of Health.

Dr. Chaudhuri completed his MD at Stanford, PhD at Caltech, and BS degrees in Biology and Computer Science at MIT. He completed his PhD in Biology under the mentorship of Nobel Laureate David Baltimore focusing on microRNAs in cancer, and his residency at Stanford University, where he did postdoctoral work with National Academy of Medicine member Maximilian Diehn demonstrating that circulating tumor DNA serves as a powerful biomarker for molecular residual disease (MRD) after curative-intent localized lung cancer treatment. Dr. Chaudhuri’s laboratory at Washington University is a translational genomics lab that focuses on the development and application of liquid biopsy cancer diagnostic technologies with the goal of more precisely personalizing solid tumor malignancy treatment. His laboratory is funded by the National Institutes of Health, the V Foundation, the Children’s Discovery Institute, the Children’s Tumor Foundation, the Alvin Siteman Cancer Research Fund, and the Melanoma Research Alliance.

Dr. Chaudhuri is also an entrepreneur in the liquid biopsy space. He co-founded Droplet Biosciences, a venture-backed startup company focused on detecting MRD after cancer surgery from lymphatic fluid. Dr. Chaudhuri additionally serves on a number of advisory boards and councils for biotechnology companies including Illumina, AstraZeneca, Daiichi Sankyo, and Roche.

Stephen G. Chun, MD

Dr. Chun is a Radiation Oncologist practicing at the MD Anderson Proton Center and West Houston Campus. As Director of Radiation Oncology Clinical Research for the MD Anderson Houston Area Locations, Dr. Chun was responsible for leading the expansion of the radiation oncology clinical trial program across the MD Anderson integrated satellite network and is supported by extramural grant funding from the National Institutes of Health as Principal Investigator. In the MD Anderson Houston Area Location satellite campuses, Dr. Chun implemented the stereotactic body radiotherapy (SBRT) program for pancreatic cancer as well as the frameless stereotactic radiosurgery (SRS) program for brain metastases. Dr. Chun is the Thoracic Radiation Oncology Quality Assurance lead across the national MD Anderson Cancer Network and is a member of the MD Anderson Institutional Review Board. With the NRG Oncology group, Dr. Chun is a member of the Radiation Oncology Committee, Lung Core Committee and Protocol Operations Management Oversight Committee. As an active clinical researcher, Dr. Chun has published in journals such as the Lancet, the Journal of Clinical Oncology, JAMA Oncology and the Journal of Thoracic Oncology.

David E. Dawe, BASc MD MSc FRCPC

Dr. David Dawe is a thoracic medical oncologist at CancerCare Manitoba and an assistant professor at the University of Manitoba. He is the medical lead for CancerCare Manitoba’s initiative focused on improving the experiences and outcomes of older adults with cancer and Chair of the CCTG SCLC Working Group. He leads research focused on investigating biomarkers, treatment patterns, and outcomes for patients with lung cancer and older patients with cancer to identify opportunities for system improvement.

Sarah Dewell, PhD, MSc., RN (she/her)

Sarah Dewell is an Assistant Professor in the School of Nursing at Thompson Rivers University. Sarah’s research explores the development of precision health through scholarship focused on nursing education, research, and practice with a focus on foundational genomic knowledge for all nurses. Sarah completed a BSc in Cell Biology and Genetics and a Masters in Medical Genetics at the University of British Columbia and a BN and a PhD in Nursing at the University of Calgary. Sarah is a member of the steering committees for the Global Genomics Nursing Alliance (G2NA) and the Canadian Nursing & Genomics initiative. She is also a member of the International Society of Nurses in Genetics (ISONG) and the Nursing Genomics Project Group of the National Human Genome Research Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG).

Desirée Hao, BA, MD, FRCPC

Kristin A. Higgins, M.D

Rosalyn Juergens, MD, PhD

Dr. Rosalyn Juergens received her medical degree from Georgetown University in Washington, D.C. She completed a fellowship in medical oncology with a focus on upper aerodigestive malignancies at The Johns Hopkins Medical Institute. Additionally, she completed her Ph.D. in Clinical Investigation at The Johns Hopkins Bloomberg School of Public Health. She was on the faculty at Johns Hopkins from 2007-2010 until she joined the faculty at McMaster University in 2011.

Dr. Juergens’ clinical expertise is in lung and esophageal cancer. She chairs the Lung Disease Site Team at the Juravinski Cancer Centre in Hamilton, Ontario. She is also a patient advocate and serves as the Medical Advisory Committee Chair for Lung Cancer Canada. She is the Head of the Department of Clinical Trials at the Juravinski Cancer Centre. She is a member of the Escarpment Cancer Research Institute and Centre for Discovery in Cancer Research.

Her areas of research expertise involve improving therapeutics and diagnostics in cancer. Her research focus has been in developmental therapeutics with a concentration on Phase I and Il clinical trials. She is the past chair of the Executive Committee of the Canadian Cancer Trials Group Investigational New Drug Committee. She is a highly sought teacher in the field of immunotherapy and has been an invited speaker across the world.

Stephen V. Liu, MD

Dr. Stephen V. Liu, MD, is a thoracic medical oncologist and an Associate Professor of Medicine at Georgetown University. He is the Director of Thoracic Oncology and the Head of Developmental Therapeutics at the Georgetown University Lombardi Comprehensive Cancer Center in Washington, DC. Dr. Liu received his undergraduate degree at Johns Hopkins University, his medical degree from the University of Maryland, and his Internal Medicine training at the University of Pennsylvania. He completed a fellowship in Hematology & Oncology at the University of Southern California and joined the faculty of Georgetown University in 2013. He is also the co-host of the official IASLC podcast, Lung Cancer Considered.

Alex Louie, MD, PhD, MSc, FRCPC

Dr. Louie is an Associate Professor, Radiation Oncologist and Clinician Scientist at Sunnybrook Health Sciences Centre, University of Toronto. During his fellowship, he obtained an MSc in Epidemiology at the Harvard School of Public Health, and a PhD from the VU University, Amsterdam. He leads the lung cancer and SBRT teams at Sunnybrook, and holds ASTRO and IASLC leadership and committee roles.

Dr. Louie has published over 200 peer-reviewed manuscripts and his research focuses on clinical trials, comparative effectiveness, economic evaluation and technology appraisal in lung, kidney and oligometastatic cancers.

Krista Noonan

Dr. Krista Noonan is a medical oncologist specializing in genitourinary and thoracic malignancies at BC Cancer, Surrey Centre and a clinical assistant professor at the University of British Columbia. She received a BSc in Biochemistry and an MD from Memorial University, Newfoundland in 2008 followed by a residency in Internal Medicine. Dr. Noonan subsequently completed her Medical Oncology and Thoracic Oncology fellowships at the BC Cancer Vancouver, as well as a diploma in Clinical Epidemiology from Memorial University. She enjoys teaching a mentoring students and residents. Her research interests’ focus are in genitourinary and thoracic malignancies and health services research.

Robert Olson MD FRCPC MSc

Dr. Olson is a clinician scientist at BC Cancer – Prince George. Clinically, he treats H&N, Breast, and Oligometastatic cancers. He is the principal investigator of the SABR-COMET-3 and SABR-5 clinical trials. In his non-oncology time, he spends time with his family of 6, plus 6 pets, or is enjoying skiing and training for triathlons.

Srinivas Raman MD, MASc, FRCPC

Dr. Srinivas Raman is a staff radiation oncologist at the Princess Margaret Cancer Centre and an assistant professor in the department of radiation oncology, University of Toronto. Srinivas previously completed a bachelor’s and master’s degree in mechanical engineering, and medical school at University of British Columbia, followed by radiation oncology residency at University of Toronto and a fellowship at BC Cancer Vancouver. His research interests are centered in applying imaging biomarkers to predict outcomes in lung cancer and evaluating technological and pharmacologic strategies to mitigate radiotherapy toxicities in lung cancer.

Bertrand Routy MD, PhD

Dr. Bertrand Routy MD, PhD is a clinician-scientist and associate professor in the department of hemato-oncology at the CHUM (University of Montreal). Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Pr. Laurence Zitvogel, Dr. Routy quickly established himself as the scientific director of the CHUM Microbiome Centre where he began his work to develop novel microbiome-based therapeutics in oncology.

His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibiotic-related gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Moreover, he demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiota- centered trials in oncology ranging from phase I to phase II trials, with the aim of decreasing primary ICI resistance.

Dr. Routy is internationally recognized as a leader in the microbiome field with more than 15,600 citations including publications in Science, Nature Medicine and Annals of oncology, and h-index of 42. Moreover, his unending commitment to improving immunotherapy responses in cancer patients has led to several awards from prestigious societies, including the FRQS 2023 Junior 2 ranked #1, the Prix de la Relève Scientifique du Québec in 2022 and the 2021 Gairdner Foundation award.

Jonathan Spicer

Dr. Spicer completed his training in Cardiothoracic Surgery at the world’s largest cancer center – University of Texas, MD Anderson Cancer Center in Houston. His clinical interests focus on minimally invasive approaches to lung cancer as well as complex resections for advanced thoracic malignancies. He has paired his clinical focus with a comprehensive research program in cancer metastasis. His laboratory studies the link between inflammation and metastasis with a particular focus on neutrophil and circulating tumor cell interactions.

Alexander Sun MD, FRCPC

Dr. Alex Sun is the Addie MacNaughton Chair in Thoracic Radiation Oncology, Princess Margaret Cancer Centre. He is a Radiation Oncologist and the Lung Cancer Site Group Leader of the Radiation Medicine Program. He is an Associate Professor in the Department of Radiation Oncology, University of Toronto. He is the Co-Chair of the Lung Disease Site Committee, Canadian Cancer Trials Group (CCTG). He is the Lead Principal Investigator of RTOG/NRG Oncology at Princess Margaret Cancer Centre and is a member of the NRG Oncology Lung Cancer Steering Committee.

His research interests include the development of clinical trials to improve outcomes in lung cancer patients through the integration of metabolic imaging in the management of lung cancer. He is the Principal Investigator of the Canadian PET-BOOST trial, a prospective randomized trial incorporating the addition of FDG-PET imaging to boost the radiation dose in locally advanced non-small cell lung cancer (LA-NSCLC).

His other research interests include the addition and combination of immunotherapy and radiotherapy. He is currently leading a prospective study of immunotherapy combined with thoracic radiotherapy in patients with advanced NSCLC. He recently lead and published the “Use of radiation therapy among patients with ES-SCLC receiving immunotherapy: Canadian consensus recommendations.”

His other area of interest is the role of Prophylactic Cranial Irradiation (PCI) in NSCLC and SCLC. He has lead multiple international clinical trials including RTOG 0214, RTOG 0937 and NRG CC003.

He has lead multiple clinical practice guidelines including the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.

He has published over 100 manuscripts in journals such as Lancet Oncology, JAMA Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, IJROBP, Radiotherapy and Oncology, Lung Cancer among others.

Paula A. Ugalde Figueroa, MD

Dr. Paula Ugalde Figueroa established herself as a thoracic surgeon dedicated to research. She has an extensive record of publications including an impressive body of work on thoracic surgery using innovative uniportal VATS approaches for lung cancer. Dr. Ugalde oversaw the creation of the lung cancer database at Laval University, and under her guidance the university became the largest contributor in the world of cases to the prospective database maintained by the International Association for the Study of Lung Cancer (IASLC).

Dr. Ugalde has served on the IASLC Board of Directors since 2021, as well as being a member of the American Association of Thoracic Surgery (AATS), Society of Thoracic Surgeons (STS), and various associated committees. Additionally, Dr. Ugalde is the acting Chair of International Affairs for the Women in Thoracic Surgery society.

She made the move to Boston, Massachusetts in the fall of 2021, where she joined the Division of Thoracic Surgery at Brigham and Women’s Hospital as an Associate Thoracic Surgeon. As part of a major teaching hospital, Dr. Ugalde is also a Member of the Faculty at Harvard Medical School and a staff member of Dana-Farber Cancer Institute.

She has helped introduce minimally invasive thoracic surgery in Brazil and Latin America by training hundreds of thoracic surgeons, including a teaching a Latin American fellow in Québec each year who then returns to his or her home country. Dr. Ugalde continues to embrace the role of being a mentor and role model to young women in thoracic surgery through her work internationally and with a focus on developing countries.

Alison Wallace, MD, PHD, FRCSC

Dr. Wallace is a thoracic surgeon with an interest in minimally invasive and robotic lung surgery.

Dr. Wallace completed her General Surgery residency and PhD at the University of British Columbia and subsequently pursued a Thoracic Surgery fellowship at the University of Toronto. Currently, Dr. Wallace serves as an Assistant Professor within the Division of Thoracic Surgery, Department of Surgery, at Dalhousie University. Within her division, she is the Director of Research and Co-Director for the QEII Lung Biobank.

In her capacity as a surgeon-scientist, Dr. Wallace focuses her research on unraveling the intricate molecular mechanisms through which various environmental exposures, including smoke and radon, contribute to the onset and progression of lung diseases such as cancer and COPD. Notably, Dr. Wallace holds two patents centered around the prevention and treatment of lung diseases, showcasing her innovative approach to addressing these health concerns.

Paul Wheatley-Price, BSc, MBChB, FRCP(UK), MD

Dr. Paul Wheatley-Price is Associate Professor in the Department of Medicine at the University of Ottawa, and a medical oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary. He is the lung cancer disease site lead in medical oncology, and also the Program Director for theUniversity of Ottawa Residency Training Program. From 2016-2021 Dr. Wheatley-Price served as President of Lung Cancer Canada, where he remains a Board member and active lung cancer advocate. Dr. Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994-1997). He received specialist medical oncology training in Wellington, New Zealand, in London, UK and finally as a Fellow in Lung Cancer Research at Princess Margaret Cancer Centre in Toronto. He has been in Ottawa since 2009.

Florence Wu, MD-PhD

Florence Wu is a PGY5 Medical Oncology resident at the University of British Columbia, where she also did her Internal Medicine residency training. Prior to this, Dr. Wu completed an MD-PhD at the University of Toronto, doing preclinical research on the use of antiangiogenic drugs (VEGF/VEGFR and Angiopoietin/Tie2 pathway-targeting agents) to reduce vascular permeability and inhibit early cancer metastasis. Dr. Wu will be seeking out further opportunities to study the crosstalk between tumor vascular biology and tumor immunology through a clinical and research fellowship in thoracic medical oncology.